ArticleClinical genetics2026
From Pathogenicity to Mechanism: A Variant Interpretation Framework for Monogenic Epilepsy.
Article in Clinical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenicity predictors exceed AUROC 0.97 on expert-curated ClinVar, yet the monogenic-epilepsy variant-of-uncertain-significance backlog persists because pathogenicity alone provides no direction-of-effect, no scalable mechanism-to-treatment mapping, and no evidence that updates as ClinVar grows. SeizeVar couples a consensus pathogenicity head (random forest plus ESM-2 LoRA cross-attention) to a gain-versus-loss-of-function mechanism classifier and a deterministic sodium-channel mechanism-direction rule. The framework was trained on a 49-gene epilepsy panel (n = 4576 labelled variants) and evaluated on six pairwise-disjoint held-out cohorts (n = 11 274) plus an external functional cohort with patch-clamp/TEVC labels (T2, n = 415). SeizeVar's mechanism head reaches honest leave-one-gene-out AUROC = 0.736 at 100% panel coverage and matches the proteome-wide specialist LoGoFunc on fair full-coverage comparison (0.770 vs. 0.760), whereas general-purpose pathogenicity predictors are mechanism-blind (AUROC ≤ 0.62). Applied to 29 293 epilepsy VUS, the pipeline returned 4708 consensus Likely-Pathogenic candidates, of which 1500 sodium-channel variants received predicted mechanism-direction labels (679 LoF-leaning, 821 GoF-leaning). By integrating pathogenicity, mechanism, and dynamic evidence on a shared probability scale, SeizeVar produces a mechanism-annotated prioritisation list to support-not replace-expert variant curation; the outputs are computational predictions and a natural next step is prospective clinical validation. Reclassified-VUS is released as a community benchmark for reclassification-aware evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.